Skip to main content
. Author manuscript; available in PMC: 2014 Dec 8.
Published in final edited form as: J Comp Neurol. 2000 Sep 18;425(2):202–218. doi: 10.1002/1096-9861(20000918)425:2<202::aid-cne4>3.0.co;2-t

Fig. 3.

Fig. 3

Camera lucida drawings of the central trigeminal tract axons following nerve growth factor (NGF; A) or neurotrophin-3 (NT-3; B) treatments from embryonic day (E)15 wholemount explant cultures. Scale bar = 100 µm.